Shrunken pore syndrome and mortality : a cohort study of patients with measured GFR and known comorbidities
(2020) In Scandinavian Journal of Clinical and Laboratory Investigation 80(5). p.412-422- Abstract
Shrunken pore syndrome (SPS) is defined by a cystatin C-based estimation of glomerular filtration rate (eGFRCYS) being less than 60% or 70% of a creatinine-based GFR estimation (eGFRCR) in the absence of extrarenal influences on cystatin C or creatinine concentrations. SPS has been associated with a substantial increase in mortality or morbidity in all investigated populations. However, in these studies, neither the diagnoses, nor causes of death were described, and only estimated GFR was available. The present study concerns 2781 individuals with measured GFR (mGFR), known diagnoses, and known causes of death during 5.6 years in median. Cox multivariate proportional hazards regression model was used to estimate hazard ratios (HR) for... (More)
Shrunken pore syndrome (SPS) is defined by a cystatin C-based estimation of glomerular filtration rate (eGFRCYS) being less than 60% or 70% of a creatinine-based GFR estimation (eGFRCR) in the absence of extrarenal influences on cystatin C or creatinine concentrations. SPS has been associated with a substantial increase in mortality or morbidity in all investigated populations. However, in these studies, neither the diagnoses, nor causes of death were described, and only estimated GFR was available. The present study concerns 2781 individuals with measured GFR (mGFR), known diagnoses, and known causes of death during 5.6 years in median. Cox multivariate proportional hazards regression model was used to estimate hazard ratios (HR) for all-cause and cancer, cardiovascular, diabetes or chronic kidney disease (CKD) as cause-specific mortality among patients with SPS. At an eGFRCYS/eGFRCR-ratio <0.70, the adjusted SPS death risk in the total cohort (HR 3.0, 95% CI 2.4-3.7) was clearly higher than that for the other diagnosis groups. In a sub-cohort of 1300 persons with or without diagnosis, but with normal mGFR, the all-cause mortality of SPS was markedly increased (HR 4.1, 95% CI 2.6-6.5). In a sub-cohort of 567 persons with normal mGFR and no diagnosis, the all-cause mortality of SPS was even more increased (HR 7.3, 95% CI 2.3-23). The prevalence of SPS in the total cohort was 23% and in the sub-cohorts 17 and 12%, respectively. As SPS is associated with a high mortality, occurs in the absence of reduced mGFR and albuminuria, it expands the spectrum of kidney disorders.
(Less)
- author
- Åkesson, Anna LU ; Lindström, Veronica LU ; Nyman, Ulf LU ; Jonsson, Magnus LU ; Abrahamson, Magnus LU ; Christensson, Anders LU ; Björk, Jonas LU and Grubb, Anders LU
- organization
-
- Division of Occupational and Environmental Medicine, Lund University
- Cystatin C, renal disease, amyloidosis and antibiotics (research group)
- Division of Clinical Chemistry and Pharmacology
- Radiology Diagnostics, Malmö (research group)
- Clinical Chemistry, Malmö (research group)
- Internal Medicine - Epidemiology (research group)
- EpiHealth: Epidemiology for Health
- EPI@LUND (research group)
- Surgery and public health (research group)
- eSSENCE: The e-Science Collaboration
- Centre for Economic Demography
- publishing date
- 2020-05-27
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Scandinavian Journal of Clinical and Laboratory Investigation
- volume
- 80
- issue
- 5
- pages
- 11 pages
- publisher
- Informa Healthcare
- external identifiers
-
- pmid:32459111
- scopus:85086327535
- ISSN
- 1502-7686
- DOI
- 10.1080/00365513.2020.1759139
- project
- AIR Lund - Artificially Intelligent use of Registers
- Shrunken Pore Syndrome (SPS) - morbidity and mortality in a population with measured glomerular filtration rate (GFR)
- language
- English
- LU publication?
- yes
- id
- b9f46580-e569-4f15-9d6e-3d714f1e743f
- date added to LUP
- 2020-06-09 12:59:01
- date last changed
- 2024-09-04 22:38:31
@article{b9f46580-e569-4f15-9d6e-3d714f1e743f, abstract = {{<p>Shrunken pore syndrome (SPS) is defined by a cystatin C-based estimation of glomerular filtration rate (eGFRCYS) being less than 60% or 70% of a creatinine-based GFR estimation (eGFRCR) in the absence of extrarenal influences on cystatin C or creatinine concentrations. SPS has been associated with a substantial increase in mortality or morbidity in all investigated populations. However, in these studies, neither the diagnoses, nor causes of death were described, and only estimated GFR was available. The present study concerns 2781 individuals with measured GFR (mGFR), known diagnoses, and known causes of death during 5.6 years in median. Cox multivariate proportional hazards regression model was used to estimate hazard ratios (HR) for all-cause and cancer, cardiovascular, diabetes or chronic kidney disease (CKD) as cause-specific mortality among patients with SPS. At an eGFRCYS/eGFRCR-ratio <0.70, the adjusted SPS death risk in the total cohort (HR 3.0, 95% CI 2.4-3.7) was clearly higher than that for the other diagnosis groups. In a sub-cohort of 1300 persons with or without diagnosis, but with normal mGFR, the all-cause mortality of SPS was markedly increased (HR 4.1, 95% CI 2.6-6.5). In a sub-cohort of 567 persons with normal mGFR and no diagnosis, the all-cause mortality of SPS was even more increased (HR 7.3, 95% CI 2.3-23). The prevalence of SPS in the total cohort was 23% and in the sub-cohorts 17 and 12%, respectively. As SPS is associated with a high mortality, occurs in the absence of reduced mGFR and albuminuria, it expands the spectrum of kidney disorders.</p>}}, author = {{Åkesson, Anna and Lindström, Veronica and Nyman, Ulf and Jonsson, Magnus and Abrahamson, Magnus and Christensson, Anders and Björk, Jonas and Grubb, Anders}}, issn = {{1502-7686}}, language = {{eng}}, month = {{05}}, number = {{5}}, pages = {{412--422}}, publisher = {{Informa Healthcare}}, series = {{Scandinavian Journal of Clinical and Laboratory Investigation}}, title = {{Shrunken pore syndrome and mortality : a cohort study of patients with measured GFR and known comorbidities}}, url = {{http://dx.doi.org/10.1080/00365513.2020.1759139}}, doi = {{10.1080/00365513.2020.1759139}}, volume = {{80}}, year = {{2020}}, }